Literature DB >> 19078760

The Clinical Features of Facioscapulohumeral Muscular Dystrophy Associated With Borderline (>/=35 kb) 4q35 EcoRI Fragments.

Kevin J Felice1, Charles H Whitaker.   

Abstract

OBJECTIVES: : The objectives of this study were to characterize the clinical features of facioscapulohumeral muscular dystrophy (FSHD) in patients with borderline (>/=35 kb) EcoRI fragments and to compare patients with borderline EcoRI fragments with FSHD patients harboring fragments of <35 kb.
BACKGROUND: : Most patients with FSHD harbor 4q35 EcoRI fragments of less than 35 kb. The clinical findings in patients with borderline fragments are not well known.
METHODS: : The authors conducted a retrospective review of patients with FSHD followed at a regional neuromuscular center over a 12-year period.
RESULTS: : Eleven patients with DNA-positive FSHD, found to harbor borderline (>/=35 kb) EcoRI fragments (group 1), were compared with 30 patients with fragments of <35 kb (group 2). Group 1 patients were less likely (18%) to present with the classic FSHD phenotype as compared with group 2 patients (63%). Statistically significant differences in clinical disease severity and manual muscle testing scores were noted between the 2 groups, with group 1 patients showing less severe weakness and disability at presentation.
CONCLUSIONS: : Patients with borderline fragments are more likely to have a partial or less severe form of FSHD, probably resulting from a less disruptive DNA alteration at the 4q35 locus.

Entities:  

Year:  2005        PMID: 19078760     DOI: 10.1097/01.cnd.0000158302.79014.c4

Source DB:  PubMed          Journal:  J Clin Neuromuscul Dis        ISSN: 1522-0443


  4 in total

1.  The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.

Authors:  Sabrina Sacconi; Richard J L F Lemmers; Judit Balog; Patrick J van der Vliet; Pauline Lahaut; Merlijn P van Nieuwenhuizen; Kirsten R Straasheijm; Rashmie D Debipersad; Marianne Vos-Versteeg; Leonardo Salviati; Alberto Casarin; Elena Pegoraro; Rabi Tawil; Egbert Bakker; Stephen J Tapscott; Claude Desnuelle; Silvère M van der Maarel
Journal:  Am J Hum Genet       Date:  2013-09-26       Impact factor: 11.025

2.  Low penetrance in facioscapulohumeral muscular dystrophy type 1 with large pathological D4Z4 alleles: a cross-sectional multicenter study.

Authors:  Emmanuelle Salort-Campana; Karine Nguyen; Rafaelle Bernard; Elisabeth Jouve; Guilhem Solé; Aleksandra Nadaj-Pakleza; Julien Niederhauser; Estelle Charles; Elisabeth Ollagnon; Françoise Bouhour; Sabrina Sacconi; Andoni Echaniz-Laguna; Claude Desnuelle; Christine Tranchant; Christophe Vial; Frederique Magdinier; Marc Bartoli; Marie-Christine Arne-Bes; Xavier Ferrer; Thierry Kuntzer; Nicolas Levy; Jean Pouget; Shahram Attarian
Journal:  Orphanet J Rare Dis       Date:  2015-01-21       Impact factor: 4.123

3.  Characterizing the face in facioscapulohumeral muscular dystrophy.

Authors:  T G J Loonen; C G C Horlings; S C C Vincenten; C H G Beurskens; S Knuijt; G W A M Padberg; J M Statland; N C Voermans; T J J Maal; B G M van Engelen; K Mul
Journal:  J Neurol       Date:  2020-10-28       Impact factor: 4.849

4.  Orofacial Muscle Weakening in Facioscapulohumeral Muscular Dystrophy (FSHD) Patients.

Authors:  Dimitrios Konstantonis; Kyriaki Kekou; Petros Papaefthymiou; Heleni Vastardis; Nikoleta Konstantoni; Maria Athanasiou; Maria Svingou; Anastasia Margariti; Angeliki Panousopoulou
Journal:  Children (Basel)       Date:  2022-01-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.